Sign In
Buy SANA
$3.13
-0.120 (-3.69%)
At Close: Jul 31, 2026
NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concer
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
09:00am, Friday, 08'th Nov 2024
Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology
Did Sana Biotechnology, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SANA
03:30pm, Thursday, 07'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concern
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
11:00am, Thursday, 07'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advi
Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated autoimmune diseases (SC291), refractory B-cell malignancies (SC262), and the fusogen platform for
Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference
04:05pm, Monday, 30'th Sep 2024
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will web
Sana Biotechnology to Present at September 2024 Investor Conferences
04:05pm, Thursday, 29'th Aug 2024
SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webc
SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of
Sana Biotechnology cuts the ribbon at new manufacturing facility near Seattle
07:12pm, Friday, 02'nd Aug 2024
Sana Biotechnology celebrated the beginning of a new chapter on its journey to make drugs that treat complicated diseases, cutting the ribbon outside the company's new manufacturing facility in Bothel
SANA Stock Earnings: Sana Biotechnology Meets EPS for Q1 2024
10:55pm, Wednesday, 08'th May 2024
Sana Biotechnology (NASDAQ: SANA ) just reported results for the first quarter of 2024. Sana Biotechnology reported earnings per share of -32 cents.
Sana Biotechnology to Present at May and June 2024 Investor Conferences
04:05pm, Monday, 06'th May 2024
SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
08:26am, Friday, 03'rd May 2024
Notable companies to have witnessed solid earnings acceleration as of now are Sana Biotechnology (SANA), LifeMD (LFMD), Evolus (EOLS) and Expro Group Holdings (XPRO).
Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX
09:02pm, Sunday, 21'st Apr 2024
Biotech stocks are having a relatively strong year as investors focus on the growing M&A in the healthcare space. Johnson & Johnson is acquiring Shockwave Medical while Novo Nordisk is buying Catalent
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
04:05pm, Thursday, 29'th Feb 2024
Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
04:05pm, Wednesday, 28'th Feb 2024
SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webc
